PPARG and urinary bladder cancer: On the one hand, PPARγ expression has been associated with good prognosis in CRC67 and the use of the PPARγ agonists troglitazone and rosiglitazone inhibited tumorigenesis in CRC and bladder cancer models by a tumor-directed effect68,69.